5-chloro-2-hydroxy-N-(3,4,5-trichloro-phenyl)benzamide | 113928-64-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-chloro-2-hydroxy-N-(3,4,5-trichloro-phenyl)benzamide
• 英文别名: 5-chloro-N-(3,4,5-trichlorophenyl)-2-hydroxybenzamide；5-chloro-2-hydroxy-benzoic acid-(3,4,5-trichloro-anilide)；5-Chlor-2-hydroxy-benzoesaeure-(3,4,5-trichlor-anilid)；5-chloro-2-hydroxy-N-(3,4,5-trichlorophenyl)benzamide
• CAS: 113928-64-6
• 化学式: C₁₃H₇Cl₄NO₂
• 分子量: 351.016
• InChiKey: PHYVFDVJERSAEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-氯代水杨酸 、 3,4,5-三氯苯胺 在 三氯化磷 作用下， 以 氯苯 为溶剂， 反应 0.42h， 以79%的产率得到5-chloro-2-hydroxy-N-(3,4,5-trichloro-phenyl)benzamide
  参考文献：
  名称：

  2-羟基-N-苯基苯甲酰胺及其酯抑制乙酰胆碱酯酶和丁酰胆碱酯酶。

  摘要：

  新型乙酰胆碱酯酶（AChE）和丁酰胆碱酯酶（BuChE）抑制剂的开发代表了减轻阿尔茨海默氏病的可行方法。合成了36种具有各种取代方式的卤代2-羟基-N-苯基苯甲酰胺（水杨酰苯胺）及其与磷基酸的酯，收率72％至92％，并进行了表征。使用改良的Ellman分光光度法评估了它们对电鳗AChE和马血清BuChE的体外抑制作用。苯甲酰胺在33.1至85.8 µM的窄浓度范围内表现出对AChE的中等抑制作用，IC50值较高。BuChE的IC50值较高（53.5-228.4 µM）。大多数衍生物比BuChE更有效地抑制AChE，并且与rivastigmine（一种用于治疗阿尔茨海默氏病的成熟胆碱酯酶抑制剂）相当或优于。磷基酯尤其具有5-氯-2-{[4-（三氟甲基）苯基]氨基甲酰基}苯基二乙基亚磷酸酯5c优越的BuChE活性（IC50 = 2.4 µM）。该衍生物也是BuChE的最选择性抑制剂。它引起了两

  DOI：

  10.3390/biom9110698

文献信息

• 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：Korea Research Institute of Bioscience and Biotechnology

  公开号：US20140221411A1

  公开（公告）日：2014-08-07

  The present invention relates to a 2-hydroxyarylamide derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient. The 2-hydroxyarylamide derivative prepared by the present invention is excellent in the inhibition of the activity of TMPRSS4 serine protease and the suppression of the infiltration of TMPRSS4-expressed cancer cells, and thus can be useful as a composition for preventing or treating cancer by inhibiting TMPRSS4 over-expressed in cancer cells, particularly, colorectal cancer, lung cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, or stomach cancer cells.

  本发明涉及一种2-羟基芳酰胺衍生物或其药用可接受的盐，其制备方法，以及作为活性成分的预防或治疗癌症的药物组合物。本发明制备的2-羟基芳酰胺衍生物在抑制TMPRSS4丝氨酸蛋白酶的活性和抑制TMPRSS4表达的癌细胞浸润方面表现出色，因此可以作为一种通过抑制癌细胞中TMPRSS4过度表达的组合物，特别是结肠癌、肺癌、乳腺癌、前列腺癌、卵巢癌、胰腺癌或胃癌细胞的预防或治疗癌症的组合物。
• Structure–activity relationships of antitubercular salicylanilides consistent with disruption of the proton gradient via proton shuttling
  作者：Ill-Young Lee、Todd D. Gruber、Amanda Samuels、Minhan Yun、Bora Nam、Minseo Kang、Kathryn Crowley、Benjamin Winterroth、Helena I. Boshoff、Clifton E. Barry

  DOI：10.1016/j.bmc.2012.10.056

  日期：2013.1

  A series of salicylanilides was synthesized based on a high-throughput screening hit against Mycobacterium tuberculosis. A free phenolic hydroxyl on the salicylic acid moeity is required for activity, and the structure-activity relationship of the aniline ring is largely driven by the presence of electron withdrawing groups. We synthesized 94 analogs exploring substitutions of both rings and the linker region in this series and we have identified multiple compounds with low micromolar potency. Unfortunately, cytotoxicity in a murine macrophage cell line trends with antimicrobial activity, suggesting a similar mechanism of action. We propose that salicylanilides function as proton shuttles that kill cells by destroying the cellular proton gradient, limiting their utility as potential therapeutics. Published by Elsevier Ltd.
• Discovery of novel 2-hydroxydiarylamide derivatives as TMPRSS4 inhibitors
  作者：Sunghyun Kang、Hye-Jin Min、Min-Seo Kang、Myung-Geun Jung、Semi Kim

  DOI：10.1016/j.bmcl.2013.01.055

  日期：2013.3

  TMPRSS4 is a novel type II transmembrane serine protease that has been implicated in the invasion and metastasis of colon cancer cells. In this study, a novel series of 2-hydroxydiarylamide derivatives were synthesized and evaluated for inhibiting TMPRSS4 serine protease activity and suppressing cancer cell invasion. These derivatives demonstrated good inhibitory activity against TMPRSS4 serine protease, which correlated with the promising anti-invasive activity of colon cancer cells overexpressing TMPRSS4. (C) 2013 Elsevier Ltd. All rights reserved.
• US9266872B2
  申请人：——

  公开号：US9266872B2

  公开（公告）日：2016-02-23
• [EN] 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT<br/>[FR] DÉRIVÉ DE 2-HYDROXYARYLAMIDE OU SEL DE QUALITÉ PHARMACEUTIQUE DE CELUI-CI, SON PROCÉDÉ DE PRÉPARATION ET COMPOSITION PHARMACEUTIQUE POUR LA PRÉVENTION OU LE TRAITEMENT DU CANCER LE CONTENANT COMME PRINCIPE ACTIF
  申请人：KOREA RES INST OF BIOSCIENCE

  公开号：WO2013058613A2

  公开（公告）日：2013-04-25

  본 발명은 2-하이드록시아릴아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 의해 제조된 2-하이드록시아릴아마이드 유도체 화합물은 TMPRSS4 세린프로테아제 활성 저해 효과와 TMPRSS4 발현 암세포 침윤 억제효과가 매우 우수하므로 암 세포, 특히, 대장암, 폐암, 유방암, 전립선암, 난소암, 췌장암 또는 위암 세포 등에서 과발현되는 TMPRSS4를 저해함으로써, 암의 예방 또는 치료용 조성물로 유용하게 사용될 수 있다.